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Background: The most important symptom as well as one of the major diagnostic criteria for eczema is itch.
Although oral antihistamines continue to be prescribed for people with eczema, it is unclear if they are effective
and safe in relieving itch and skin lesions. We sought to evaluate the available evidence on effectiveness of oral
antihistamines (H1 antagonists) as monotherapy in children and adults with eczema.
Methods: Searches included 10 databases and trial registers as well as conference proceedings (January 2014).
Randomised controlled trials that assessed the effects of oral H1 antihistamines as monotherapy in children and
adults with eczema were included.
Results: Our searches retrieved 757 references, but no randomised controlled trial met our inclusion criteria. Most
studies allowed concomitant treatments, making the assessment of the individual effects of oral H1 antihistamines
impossible.
Conclusions: There is currently no high-level evidence to support or refute the efficacy or safety of oral H1
antihistamines used as monotherapy for eczema. A further review of studies that assesses the effects of oral H1
antihistamines as ‘add-on’ therapy together with concomitant treatments is warranted to determine the beneficial
effects of this group of medications in the treatment of eczema.
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Eczema is a common chronic inflammatory skin disease
with an estimated prevalence ranging from 2% to ap-
proximately 20% worldwide [1,2]. The concurrent use of
terms such as “eczema”, “atopic eczema”, “atopic derma-
titis”, “atopic eczema/dermatitis syndrome” and “neu-
rodermatitis” has led to confusion and inconsistency in
their application. Therefore, the nomenclature review
committee of the World Allergy Organization has pro-
posed the use of "eczema" as a unifying term, and this
term is also used throughout the text of this review [3].
The majority of cases occur before the age of 5 years
and, although eczema often resolves during childhood or* Correspondence: e.j.van_zuuren@lumc.nl
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article, unless otherwise stated.adolescence, relapses do occur and the disease can per-
sist into adult life [4]. Itch is the most important symp-
tom with a major impact on health-related quality of life
[5]. It is one of the major diagnostic criteria for eczema,
and without itch the diagnosis of eczema cannot be con-
firmed [4]. A wide range of options are available for the
treatment of eczema and antihistamines are often pre-
scribed to relieve the associated itch [4]. Although the
exact role of histamine in itch still needs to be eluci-
dated and it remains unclear if oral antihistamines are
effective in the management of eczema, they continue to
be prescribed by physicians.
This is a summary of a Cochrane systematic review
that was conducted to assess the effects of oral antihista-
mines (H1 antagonists) as monotherapy in children and
adults with eczema [4].ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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A systematic review of randomised controlled trials (RCTs)
according to a prespecified protocol [4].
Search strategies
We searched for relevant studies in 10 electronic data-
bases and trial registers up to January 2014 (see Table 1).
The bibliographies of the excluded studies were exam-
ined for further references to potentially eligible RCTs
(EJvZ) and two review authors searched for ongoing and
unpublished trials in January 2014 (EJvZ and UM).
Abstracts from the International Research Workshops
on eczema and itch, the conference proceedings of the
European Academy of Dermatology and Venereology,
and of the European Academy of Allergy and Clinical
Immunology from 2000 to 2011 were screened, in order
to identify further potentially relevant RCTs (EJvZ, UM,
and EW). No language restrictions were imposed. Four
review authors independently assessed the titles and ab-
stracts for eligible RCTs (CJA, EJvZ, ZF and AJ).
Inclusion/exclusion criteria
Inclusion criteria were RCTs in children and adults with
a clinical diagnosis of eczema identified as ‘atopic eczema’
or ‘eczema’ that compared oral antihistamines (H1-
antagonists) of all classes (sedating, non-sedating) as
monotherapy versus placebo or alternative treatment
(for example, topical corticosteroids or topical immu-
nomodulators). We excluded studies investigating the
following interventions and comparisons: one antihis-
tamine versus another antihistamine; and topical antihis-
tamines and H1 antihistamines as 'add-on' therapy other
than emollients/moisturisers.
Outcome measures
Our two primary outcomes were (i) reduction of subjec-
tively perceived itch, as determined by validated ratingTable 1 Electronic databases and trial registers searched
Electronic databases Trial registers
The Cochrane Skin Group
Specialised Register
The metaRegister of Controlled Trials
www.controlled-trials.com
The Cochrane Central Register
of Controlled Trials MEDLINE
The US National Institutes of
Health Ongoing Trials Register
(www.clinicaltrials.gov)
EMBASE The Australian and New Zealand Clinical
Trials Registry (www.anzctr.org.au)
LILACS The World Health Organization
International Clinical Trials Registry
platform www.who.int/trialsearch
The Ongoing Skin Trials Register on
www.nottingham.ac.uk/ongoingskintrialsscales (for example, visual analogue scales) and (ii) global
improvement in eczema, as measured by reduction in an
eczema severity score such as SCORAD [6] or any other
scoring scale. Secondary outcomes were percentage of
participants reporting adverse effects/adverse events, and
improvement in quality of life measures using any generic
or disease-specific instrument.
Data extraction and synthesis
No studies met our inclusion criteria. If any eligible
studies are identified for future updates of the Cochrane
review, the following methods of data extraction and
synthesis will apply. Study details will be extracted and
summarised using a structured data extraction form by
two review authors. Risk of bias will be independently
assessed for each included study using the Cochrane
Collaboration’s domain-based evaluation tool as descri-
bed in Chapter 8, Section 8.5, in the Cochrane Handbook
for Systematic Reviews of Interventions [7]. For the statis-
tical analysis, dichotomous outcomes will be presented
as relative risk ratios and continuous outcomes as mean
differences if the same measurement scales have been
used across trials. Standardised mean differences will be
used to express results for continuous outcomes if differ-
ent, but comparable, measurement scales have been used
across trials. All outcomes data will be reported with
their associated 95% confidence intervals. We will per-
form a meta-analysis for studies with similar types of
interventions to calculate a weighted treatment effect
across the trials, using a random effects model. Clinical
heterogeneity will be assessed by examining the charac-
teristics of the studies, in terms of the similarity between
the types of participants, the interventions and the cor-
responding outcomes. Statistical heterogeneity will be
assessed using a Chi2 test and the I2 statistic. We will re-
port heterogeneity as moderate to high for I2 values be-
tween 30% and 60% and as substantial between 50% and
90% [7].
Results
From the searches we identified 757 studies which, after
removal of the duplicates, provided a total of 748 cita-
tions (see Figure 1). After examination of the titles and
abstracts a further 712 ineligible studies were eliminated.
Full text copies of the remaining 36 studies were ob-
tained and these were assessed independently for eli-
gibility by four authors (CJA, EJvZ, ZF and AJ). No
ongoing trials matching our inclusion criteria were iden-
tified nor were any eligible studies found after screening
the abstracts of all of the potentially relevant conference
proceedings. Finally, 35 out of the 36 remaining studies
were excluded and one study is pending assessment as
we await a reply from the principal investigator about
missing and incomplete trial details [8]. The majority
Figure 1 Search results.
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concomitant treatments which were pre-specified as ex-
clusion criteria for study eligibility in this systematic
review. A further eight studies were excluded as these
compared one antihistamine with another antihistamine,
which was another pre-specified exclusion criterion. WeTable 2 Oral H1 antihistamines compared to placebo or alter
Illustrative comparative risks*
(95% CI)
Assumed risk Corresponding
risk
Outcomes Placebo or
alternative
treatment
Oral H1
antihistamines
Reduction of subjectively perceived
itch, as determined by validated
rating scales
- -
Global improvement in eczema, as
measured by reduction in an eczema
severity score such as SCORAD
- -
Percentage of participants reporting
adverse effects/adverse events
- -
Improvement in quality of life measures - -
Patient or population: patients with eczema. Intervention: oral H1 antihistamines. C
versus another antihistamine; topical antihistamines; H1 antihistamines as 'add-on'
moisturizers).
*The basis for the assumed risk (for example, the median control group risk across
based on the assumed risk in the comparison group and the relative effect of the i
GRADE Working Group grades of evidence: high quality, further research is very un
further research is likely to have an important impact on our confidence in the esti
very likely to have an important impact on our confidence in the estimate of effect
about the estimate.
1There might be some evidence coming from studies that allowed concomitant the
antihistamines on eczema.excluded the remainder (9) for other reasons (for example,
non-RCTs or other skin diseases).
Discussion
Unfortunately no RCTs could be included in our Co-
chrane review (see Table 2). Most of the studies retrievednative treatment for eczema: summary of findings [9]
Relative effect
(95% CI)
No of
participants
(studies)
Quality of the
evidence (GRADE)
Comments
Not estimable 0 (0) No evidence from RCTs
that met our inclusion
criteria1
No RCT could
be included
Not estimable 0 (0) No evidence from RCTs
that met our inclusion
criteria1
No RCT could
be included
Not estimable 0 (0) No evidence from RCTs
that met our inclusion
criteria1
No RCT could
be included
Not estimable 0 (0) No evidence from RCTs
that met our inclusion
criteria1
No RCT could
be included
omparison: placebo or alternative treatment (excluding: one antihistamine
therapy; and studies using any concomitant therapy other than emollients/
studies) is provided in footnotes. The corresponding risk (and its 95% CI) is
ntervention (and its 95% CI).
likely to change our confidence in the estimate of effect; moderate quality,
mate of effect and may change the estimate; low quality, further research is
and is likely to change the estimate; very low quality, we are very uncertain
rapies for eczema, but that would not address the singular effect of oral
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antihistamines as 'add-on' therapy to other topical or
systemic treatment, and consequently did not permit
reliable assessments to be made of the individual ef-
fects of H1 antihistamines. Topical and/or systemic
treatments used concomitantly should be regarded
as modifiers of the individual effect of the H1 anti-
histamines and can potentially confound any assess-
ment of their efficacy.
Although oral H1 antihistamines (especially of the
sedating type) are widely prescribed for the relief of
itch, our systematic review indicates that there is cur-
rently a lack of evidence to support or refute the use
of H1 antihistamines alone in the management of
eczema.
In an earlier review, in which the authors aimed to
summarize the evidence for the efficacy of oral H1 anti-
histamines in relieving itch in people with eczema, it
was concluded that most studies were underpowered,
suffered from flawed study designs and that there was
little objective evidence for the efficacy of antihistamines
for itch relief in eczema patients [10]. A similar conclu-
sion was reached in a more recent review [11]. However,
although we are in broad agreement with the conclu-
sions drawn by the authors of both reviews, they failed
to address the potential confounding effect of the add-
itional concomitant treatments.
A further systematic review is planned, which will in-
clude studies allowing the use of concomitant therapies.
This might help fill the gaps in the evidence, in particu-
lar by demonstrating the benefit or otherwise of oral H1
antihistamines used as add-on therapy.
Conclusion
The results of this systematic review demonstrate that,
despite the fact that clinicians continue to prescribe oral
H1 antihistamines to patients with eczema, there is
no reliable high-level evidence to support this clinical
decision. No randomised trials comparing an oral H1
antihistamine with placebo or control were found, and
although there are circumstances in health care where
randomised trials are unnecessary because the effects
of an intervention are so marked, this is not the case
for oral H1 antihistamines. We realise that the ori-
ginal, but apparently untested, idea behind the use of
this class of drugs in eczema might have been their
sedative effect, but even this rationale is surely now
undermined by the use of newer drugs that cause lit-
tle or no sedation. It would appear that oral H1 an-
tihistamines bypassed what should be the key first
step before the introduction of a drug for the treat-
ment of a condition as common as eczema, namely
research to prove the concept that the drug is better
than nothing.Endnotes
This paper is based on a Cochrane review published in
Issue 2, February 2013 of The Cochrane Library (see
http://www.CochraneLibrary.net for further information)
[4]. Cochrane reviews are regularly updated as new evi-
dence emerges and in response to comments and criti-
cisms. The Cochrane Library should be consulted for
the most recent version of this review.
Abbreviation
RCT: randomised controlled trial.
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